Search research articles
Contact Us
Filters
Showing results (1-10 of 130) with videos related to
Page
of 13
Sort By:
JAMA Network Open
|
July 11, 2020
Plasma Apolipoprotein E Levels and Risk of Dementia-You Are the Company You Keep
Madhav Thambisetty
Biomarkers in Medicine
|
December 8, 2010
Do extracellular chaperone proteins in plasma have potential as Alzheimer's disease biomarkers?
Madhav Thambisetty
American Journal of Physiology. Cell Physiology
|
June 16, 2017
Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse"
Madhav Thambisetty
Biomarkers in Medicine
|
April 14, 2010
Blood-based biomarkers of Alzheimer's disease: challenging but feasible
Madhav Thambisetty, Simon Lovestone
JAMA
|
May 6, 2024
Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering
Madhav Thambisetty, Robert Howard
Journal of the American Geriatrics Society
|
April 16, 2014
Soluble interleukin-6 receptor levels and risk of dementia: one more signpost on a long road ahead
Madhav Thambisetty, Luigi Ferrucci
Nature Reviews. Neurology
|
January 7, 2023
Lecanemab trial in AD brings hope but requires greater clarity
Madhav Thambisetty, Robert Howard
JAMA Neurology
|
March 13, 2023
Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain
Madhav Thambisetty, Robert Howard
Expert Review of Molecular Diagnostics
|
September 7, 2004
Diagnosis and management of MELAS
Madhav Thambisetty, Nancy J Newman
Biomarkers in Medicine
|
March 15, 2018
α2-macroglobulin in Alzheimer's disease: new roles for an old chaperone
Sahba Seddighi, Vijay Varma, Madhav Thambisetty
Page
of 13
Search research articles
Search
Showing results (1-10 of 130) with videos related to
Sort By:
Page
of 13
JAMA Network Open
|
July 11, 2020
Plasma Apolipoprotein E Levels and Risk of Dementia-You Are the Company You Keep
Madhav Thambisetty
Biomarkers in Medicine
|
December 8, 2010
Do extracellular chaperone proteins in plasma have potential as Alzheimer's disease biomarkers?
Madhav Thambisetty
American Journal of Physiology. Cell Physiology
|
June 16, 2017
Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse"
Madhav Thambisetty
Biomarkers in Medicine
|
April 14, 2010
Blood-based biomarkers of Alzheimer's disease: challenging but feasible
Madhav Thambisetty, Simon Lovestone
JAMA
|
May 6, 2024
Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering
Madhav Thambisetty, Robert Howard
Journal of the American Geriatrics Society
|
April 16, 2014
Soluble interleukin-6 receptor levels and risk of dementia: one more signpost on a long road ahead
Madhav Thambisetty, Luigi Ferrucci
Nature Reviews. Neurology
|
January 7, 2023
Lecanemab trial in AD brings hope but requires greater clarity
Madhav Thambisetty, Robert Howard
JAMA Neurology
|
March 13, 2023
Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain
Madhav Thambisetty, Robert Howard
Expert Review of Molecular Diagnostics
|
September 7, 2004
Diagnosis and management of MELAS
Madhav Thambisetty, Nancy J Newman
Biomarkers in Medicine
|
March 15, 2018
α2-macroglobulin in Alzheimer's disease: new roles for an old chaperone
Sahba Seddighi, Vijay Varma, Madhav Thambisetty
Page
of 13